Mecamylamine for the Treatment of Patients With Depression and Alcohol Dependence
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The objective of this study is to evaluate the efficacy of mecamylamine (MEC, 10 mg/day)
versus placebo in reducing depressive and alcohol symptoms in patients with depression and
co-morbid alcohol dependence. The researchers hypothesize that MEC will significantly reduce
depressive symptoms and decrease alcohol consumption compared to placebo in patients with
depression and alcohol dependence who are on a stable dose of a selective serotonin reuptake
inhibitor (SSRI).
Phase:
Phase 3
Details
Lead Sponsor:
Yale University
Collaborator:
National Alliance for Research on Schizophrenia and Depression